[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality].
The final goal of CKD-MBD (chronic kidney disease, mineral and bone disorder) is to reduce the risk of death in uremic patients. To achieve this objective, it is of importance to manage laboratory abnormalities, bone abnormalities, and vascular calcification appropriately. Many observation studies suggested that the good control of serum phosphate, calcium, and PTH concentration would lead to the lower risk of death. Fracture and vascular calcification would increase the risk for mortality. In addition, some randomized clinical trials have shown that the use of CKD-MBD related drugs, e.g. vitamin D, phosphate binder, might lead to reductions in the risk of death.
Taniguchi
Masatomo
M
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University.
D001851:Bone Diseases, Metabolic / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000401:mortality*; D002114:Calcinosis; D002118:Calcium / Q000378:metabolism; D002908:Chronic Disease; D000069449:Cinacalcet; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality*; D009281:Naphthalenes / Q000627:therapeutic use; D010281:Parathyroid Hormone / Q000378:metabolism; D010758:Phosphorus / Q000378:metabolism; D011073:Polyamines / Q000627:therapeutic use; D011379:Prognosis; D012306:Risk; D000069603:Sevelamer; D015996:Survival Rate; D014652:Vascular Diseases; D014807:Vitamin D / Q000627:therapeutic use
D009281:Naphthalenes; D010281:Parathyroid Hormone; D011073:Polyamines; D014807:Vitamin D; D010758:Phosphorus; D000069603:Sevelamer; D002118:Calcium; D000069449:Cinacalcet